RISK AND FORECAST FOR THE DEVELOPMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH RHEUMATOID ARTHRITIS

Abstract

 Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease that primarily manifests as destructive joint damage but, as a systemic disease, affects many organs and systems of the body, including the cardiovascular system. Epidemiological and clinical studies conducted in recent years indicate a significantly higher risk of developing cardiovascular diseases (CVD) in RA patients.

This article provides a comprehensive analysis of the main risk factors for the development of gastrointestinal diseases in RA patients, their pathogenetic mechanisms, and their impact on clinical prognosis. According to modern scientific data, the risk of developing cardiovascular diseases in RA patients is on average 1.5–2 times higher than in the general population, and in some cases, this indicator can even reach 2.5 times. In particular, the likelihood of developing myocardial infarction, stroke, heart failure, and peripheral artery diseases increases.

Chronic systemic inflammation plays a leading role in the pathogenesis of the disease. Biomarkers such as inflammatory mediators - interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and C-reactive protein (CRP) - cause damage not only to joint tissues but also to the vascular wall. As a result, endothelial dysfunction, oxidative stress, and the formation of atherosclerotic plaques accelerate. These processes lead to early atherogenesis and the development of rapidly progressive atherosclerosis.

Furthermore, metabolic changes associated with RA, specifically lipid metabolism disorders ("lipid paradox"), insulin resistance, and a procoagulant state, further increase cardiovascular risk. Traditional risk factors—arterial hypertension, smoking, obesity, and dyslipidemia—have a more pronounced effect against the background of RA.

The duration and activity level of the disease directly affect the prognosis. In patients with long-term and high-activity RA, the probability of developing cardiovascular complications is significantly higher. Long-term use of glucocorticosteroids and certain non-traditional anti-inflammatory drugs is also among the factors that increase cardiovascular risk.

At the same time, modern treatment strategies, particularly disease-modifying antirheumatic drugs (DMARDs), biological agents (anti-TNF, IL-6 inhibitors), and targeted therapy agents, play an important role in reducing cardiovascular risk through effective inflammation control. RA is not only a joint disease but also a systemic pathology associated with high cardiovascular risk. Therefore, early detection of cardiovascular risk, comprehensive assessment, and the application of individual preventive and therapeutic strategies are of great importance in the management of RA patients.